Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Timothy J Purwin"'
Autor:
Vivian Chua, Marlana Orloff, Jessica LF Teh, Takahito Sugase, Connie Liao, Timothy J Purwin, Bao Q Lam, Mizue Terai, Grazia Ambrosini, Richard D Carvajal, Gary Schwartz, Takami Sato, Andrew E Aplin
Publikováno v:
EMBO Molecular Medicine, Vol 11, Iss 2, Pp 1-16 (2019)
Abstract Alterations in transcriptional programs promote tumor development and progression and are targetable by bromodomain and extraterminal (BET) protein inhibitors. However, in a multi‐site clinical trial testing the novel BET inhibitor, PLX511
Externí odkaz:
https://doaj.org/article/ad9494b5987a443bb7fdef74004cf81b
Publikováno v:
iScience, Vol 26, Iss 9, Pp 107472- (2023)
Summary: Evidence is mounting for cross-resistance between immune checkpoint and targeted kinase inhibitor therapies in cutaneous melanoma patients. Since the loss of the transcription factor, SOX10, causes tolerance to MAPK pathway inhibitors, we us
Externí odkaz:
https://doaj.org/article/1590bf7b7273462993c0937a95c0c89c
Autor:
Claudia Capparelli, Timothy J. Purwin, McKenna Glasheen, Signe Caksa, Manoela Tiago, Nicole Wilski, Danielle Pomante, Sheera Rosenbaum, Mai Q. Nguyen, Weijia Cai, Janusz Franco-Barraza, Richard Zheng, Gaurav Kumar, Inna Chervoneva, Ayako Shimada, Vito W. Rebecca, Adam E. Snook, Kim Hookim, Xiaowei Xu, Edna Cukierman, Meenhard Herlyn, Andrew E. Aplin
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Mechanisms underlying tumor cell plasticity remain poorly understood. Here, the authors show the presence of a dormant-invasive SOX10- subpopulation in cutaneous melanoma that can be targeted by cIAP1/2 inhibitors.
Externí odkaz:
https://doaj.org/article/59cac3fded2d4f39825e28a5697d2477
Autor:
Sheera R. Rosenbaum, Meghan Knecht, Mehri Mollaee, Zhijiu Zhong, Dan A. Erkes, Peter A. McCue, Inna Chervoneva, Adam C. Berger, Jennifer A. Lo, David E. Fisher, Jeffrey E. Gershenwald, Michael A. Davies, Timothy J. Purwin, Andrew E. Aplin
Publikováno v:
Cell Reports, Vol 30, Iss 2, Pp 510-524.e6 (2020)
Summary: Immune checkpoint inhibitors have improved patient survival in melanoma, but the innate resistance of many patients necessitates the investigation of alternative immune targets. Many immune checkpoint proteins lack proper characterization, i
Externí odkaz:
https://doaj.org/article/f3f247ef43da49c78f8d6684b25f14af
Autor:
Aplin, Anna Han, Dzmitry Mukha, Vivian Chua, Timothy J. Purwin, Manoela Tiago, Bhavik Modasia, Usman Baqai, Jenna L. Aumiller, Nelisa Bechtel, Emily Hunter, Meggie Danielson, Mizue Terai, Philip B. Wedegaertner, Takami Sato, Solange Landreville, Michael A. Davies, Stefan Kurtenbach, J. William Harbour, Zachary T. Schug, Andrew E.
Publikováno v:
Cancers; Volume 15; Issue 13; Pages: 3451
Uveal melanoma (UM) displays a high frequency of metastasis; however, effective therapies for metastatic UM are limited. Identifying unique metabolic features of UM may provide a potential targeting strategy. A lipid metabolism protein expression sig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::b28f5cc1baa42f552d8710310248e0a9
Autor:
Jeffrey L. Benovic, Julio Aguirre-Ghiso, Andrew E. Aplin, Philip B. Wedegaertner, Naiming Zhou, Gregory G. Tall, Takami Sato, Mizue Terai, Shihua Wu, Lihong Zhang, Thomas H. Charpentier, Dougan McGrath, Timothy J. Purwin, Clinita E. Randolph, Eduardo Farias, Dominic Lapadula
GNAQ and GNA11 sequence analysis of UM002B cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc86c2aecfa02c9d2318332d673c3913
https://doi.org/10.1158/1541-7786.22513482.v1
https://doi.org/10.1158/1541-7786.22513482.v1
Supplementary Figures 1-5 from Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma
Autor:
Andrew E. Aplin, Julio Aguirre-Ghiso, Michael A. Davies, Takami Sato, Nelisa Bechtel, Connie Liao, Usman Baqai, Prem Patel, Vivian Chua, Anna Han, Timothy J. Purwin, Jessica L.F. Teh
Supplemental Figure 1. CDK4/6i + MEKi treatment does not modulate proteins within the apoptotic signaling pathway. Supplemental Figure 2. Growth of UM001 xenografts treated with MEKi and/or CDK4/6i. Supplemental Figure 3. RNA-seq samples cluster base
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85006f5b1b7ea2fe04bccacbd4f5ada8
https://doi.org/10.1158/1535-7163.22521028
https://doi.org/10.1158/1535-7163.22521028
Autor:
Andrew E. Aplin, Gideon Bollag, Karen E. Knudsen, Matthew J. Schiewer, Michael A. Davies, Allison Goldberg, Timothy J. Purwin, Adam C. Berger, Michael J. Vido, Curtis H. Kugel, Edward J. Hartsough
Supplemental Figure 1: PLX8394 does not alter CRAF or c-Src phosphorylation; Supplemental Figure 2. Treatment of xenograft-derived tumor pieces in an ex vivo explant system; Supplemental Figure 3: Patient sample extended data; Supplemental Figure 4:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f754036ede2f21641c61c659cdbc635
https://doi.org/10.1158/1535-7163.22509490
https://doi.org/10.1158/1535-7163.22509490
Autor:
Andrew E. Aplin, Reinhard Dummer, Mitch P. Levesque, Lawrence N. Kwong, Michael A. Davies, Kim HooKim, Ines Kleiber, Paolo M. Fortina, Adam Ertel, Inna Chervoneva, Prem Patel, Neda Nikbakht, Timothy J. Purwin, Phil F. Cheng, Jessica L.F. Teh
Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::279be8361973204419e794552ad613e1
https://doi.org/10.1158/2159-8290.c.6546826
https://doi.org/10.1158/2159-8290.c.6546826
Autor:
Andrew E. Aplin, Gideon Bollag, Karen E. Knudsen, Matthew J. Schiewer, Michael A. Davies, Allison Goldberg, Timothy J. Purwin, Adam C. Berger, Michael J. Vido, Curtis H. Kugel, Edward J. Hartsough
FDA-approved BRAF inhibitors produce high response rates and improve overall survival in patients with BRAF V600E/K–mutant melanoma, but are linked to pathologies associated with paradoxical ERK1/2 activation in wild-type BRAF cells. To overcome th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0fa2f2b31c388debfefa1f6c1d3899d
https://doi.org/10.1158/1535-7163.c.6539317.v1
https://doi.org/10.1158/1535-7163.c.6539317.v1